Sedana Medical publishes its Annual Report for 2022

Sedana Medical AB (publ) publishes its Annual Report for 2022. The Annual Report describes important events and financial information for 2022, as well as the progress the company has made on its strategic priorities during the year.

“In 2022, we took several important steps closer to our vision – to make inhaled sedation a global standard therapy for mechanically ventilated patients in intensive care. The first patient was included in the clinical programme in the United States, NICE in the UK recommended Sedaconda ACD as a cost-saving option and the first bottles of Sedaconda (isoflurane) were sold in Europe. In early 2023, the therapy was granted Fast Track Designation by the United States FDA and the company’s share was listed on Nasdaq Stockholm", says Johannes Doll, President and CEO of Sedana Medical.

The Annual Report is available at www.sedanamedical.com.

For additional information, please contact:
Johannes Doll, CEO, +46 (0)76 303 66 66
Johan Spetz, CFO, +46 (0)730 36 37 89
ir@sedanamedical.com

This information is information that Sedana Medical is obliged to make public pursuant to the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, on 3 April 2023 at 19:00 CEST.

About Sedana Medical

Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient’s life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care.

Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordics, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors.

Sedana Medical was founded in 2005, is listed on Nasdaq Stockholm (SEDANA) and headquartered in Stockholm, Sweden.